These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

448 related items for PubMed ID: 17876741

  • 1. [Natalizumab in the treatment of multiple sclerosis].
    Horga A, Horga de la Parte JF.
    Rev Neurol; ; 45(5):293-303. PubMed ID: 17876741
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.
    Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW, SENTINEL Investigators.
    N Engl J Med; 2006 Mar 02; 354(9):911-23. PubMed ID: 16510745
    [Abstract] [Full Text] [Related]

  • 3. Natalizumab: new drug. Multiple sclerosis: risky market approval.
    Prescrire Int; 2008 Feb 02; 17(93):7-10. PubMed ID: 18354844
    [Abstract] [Full Text] [Related]

  • 4. Natalizumab: targeting alpha4-integrins in multiple sclerosis.
    Engelhardt B, Kappos L.
    Neurodegener Dis; 2008 Feb 02; 5(1):16-22. PubMed ID: 18075270
    [Abstract] [Full Text] [Related]

  • 5. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
    Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Neurology; 2007 Oct 02; 69(14):1391-403. PubMed ID: 17761550
    [Abstract] [Full Text] [Related]

  • 6. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis.
    Johnson KP.
    Neurologist; 2007 Jul 02; 13(4):182-7. PubMed ID: 17622909
    [Abstract] [Full Text] [Related]

  • 7. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 02; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 8. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 02; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 9. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
    Rudick RA, Sandrock A.
    Expert Rev Neurother; 2004 Jul 02; 4(4):571-80. PubMed ID: 15853576
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, AFFIRM and SENTINEL Investigators.
    Ann Neurol; 2007 Oct 02; 62(4):335-46. PubMed ID: 17696126
    [Abstract] [Full Text] [Related]

  • 11. The role of natalizumab in the treatment of multiple sclerosis.
    Coyle PK.
    Am J Manag Care; 2010 Jun 02; 16(6 Suppl):S164-70. PubMed ID: 20615052
    [Abstract] [Full Text] [Related]

  • 12. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
    Ko HH, Bressler B.
    Expert Rev Gastroenterol Hepatol; 2007 Oct 02; 1(1):29-39. PubMed ID: 19072431
    [Abstract] [Full Text] [Related]

  • 13. Recommendations for the selection, treatment, and management of patients utilizing natalizumab therapy for multiple sclerosis.
    Foley J.
    Am J Manag Care; 2010 Jun 02; 16(6 Suppl):S178-83. PubMed ID: 20615054
    [Abstract] [Full Text] [Related]

  • 14. [Natalizumab in multiple sclerosis: unclear patient benefits].
    Schipper JP.
    Ned Tijdschr Geneeskd; 2007 Apr 14; 151(15):852-5. PubMed ID: 17472115
    [Abstract] [Full Text] [Related]

  • 15. Treating multiple sclerosis with natalizumab.
    Iaffaldano P, Lucchese G, Trojano M.
    Expert Rev Neurother; 2011 Dec 14; 11(12):1683-92. PubMed ID: 22091593
    [Abstract] [Full Text] [Related]

  • 16. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR, Panitch HS.
    Clin Ther; 2007 Sep 14; 29(9):2031-48. PubMed ID: 18035202
    [Abstract] [Full Text] [Related]

  • 17. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.
    Mult Scler; 2009 Aug 14; 15(8):984-97. PubMed ID: 19667023
    [Abstract] [Full Text] [Related]

  • 18. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Neurology; 2008 Sep 02; 71(10):766-73. PubMed ID: 18765653
    [Abstract] [Full Text] [Related]

  • 19. The effects of natalizumab on the innate and adaptive immune system in the central nervous system.
    Stüve O.
    J Neurol Sci; 2008 Nov 15; 274(1-2):39-41. PubMed ID: 18474372
    [Abstract] [Full Text] [Related]

  • 20. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis.
    Kleinschmidt-DeMasters BK, Tyler KL.
    N Engl J Med; 2005 Jul 28; 353(4):369-74. PubMed ID: 15947079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.